ストックスクリーナーアプリを入手
51.09
2.09%
-1.09
前日終値:
$52.18
開ける：
$51.64
24時間の取引高:
623.68K
Relative Volume:
0.46
時価総額：
$3.65B
収益：
-
当期純損益:
$-98.78M
株価収益率:
-30.71
EPS:
-1.6638
ネットキャッシュフロー:
$-65.60M
1週間 パフォーマンス:
+2.55%
1か月 パフォーマンス:
+38.08%
6か月 パフォーマンス:
+96.50%
1年 パフォーマンス:
+124.28%
1日の値動き範囲:
$49.51
$51.76
1週間の範囲:
$48.52
$52.38
52週間の値動き範囲:
$14.79
$52.39
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Compare ELVN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
51.09 | 3.65B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-16 | 開始されました | Goldman | Buy |
| 2024-12-13 | 開始されました | BTIG Research | Buy |
| 2024-09-09 | 開始されました | H.C. Wainwright | Buy |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-09 | 開始されました | Mizuho | Buy |
| 2023-03-29 | 開始されました | Jefferies | Buy |
すべてを表示
Enliven Therapeutics Inc (ELVN) 最新ニュース
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know - MSN
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64 - Moomoo
Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright raises Enliven Therapeutics price target on trial data By Investing.com - Investing.com Canada
ELVN Maintained by HC Wainwright & Co. -- Price Target Raised to $64 - GuruFocus
Insider Sell Alert: Lori Kunkel Sells 10,000 Shares of Enliven T - GuruFocus
Enliven Therapeutics (ELVN) Fell Out Of Russell Indexes, But Is The Valuation Already Rich? - simplywall.st
Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing - marketscreener.com
Enliven Therapeutics (ELVN) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - AOL.com
How Enliven Therapeutics Inc. (ELVN) Affects Rotational Strategy Timing - Stock Traders Daily
Enliven Therapeutics stock hits 52-week high at $40.66 - Investing.com
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags - Yahoo Finance
ELVN Maintained by Stifel -- Price Target Raised to $80 - GuruFocus
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $80 - Moomoo
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN? - AOL.com
ELVN Maintained by Jones Trading -- Price Target Raised to $70.0 - GuruFocus
Jones Trading raises Enliven Therapeutics price target on CML trials By Investing.com - Investing.com South Africa
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Jones Trading raises Enliven Therapeutics price target on CML trials - Investing.com
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Enliven Therapeutics, Inc.(NasdaqGS: ELVN) dropped from Russell Microcap Index - marketscreener.com
Enliven Therapeutics, Inc.(NasdaqGS: ELVN) dropped from Russell 3000E Index - marketscreener.com
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% - Yahoo Finance
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally - AOL.com
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally - The Motley Fool
Enliven Therapeutics, Inc. Actuals & Estimates (NASDAQ:ELVN) - TradingView
ELVN Forecast — Price Target — Prediction for 2027 - TradingView
(ELVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
22% Below Analyst Target, Is Enliven Therapeutics (ELVN) Fairly Valued Here - Sahm
OrbiMed entities sell $39 million in Enliven Therapeutics stock By Investing.com - Investing.com Nigeria
Enliven Therapeutics(ELVN.US) 10% Shareholder Sells US$39.01 Million in Common Stock - Moomoo
Form 4 Enliven Therapeutics Inc For: 24 June By Investing.com - Investing.com South Africa
OrbiMed entities sell $39 million in Enliven Therapeutics stock - Investing.com UK
Form 13D/A Enliven Therapeutics For: 24 June By Investing.com - Investing.com South Africa
OrbiMed funds trim Enliven Therapeutics (NASDAQ: ELVN) stake with 860K-share sale - Stock Titan
OrbiMed cuts Enliven Therapeutics (ELVN) holdings to 9.5% of shares - Stock Titan
ETFs Investing in Enliven Therapeutics, Inc. Stocks - TradingView
Enliven Therapeutics stock hits 52-week high at 48.55 USD By Investing.com - Investing.com India
Enliven Therapeutics stock hits 52-week high at 48.55 USD - Investing.com UK
Enliven Therapeutics Inc (ELVN) 財務データ
収益
当期純利益
現金流量
EPS
Enliven Therapeutics Inc (ELVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Jun 22 '26 |
Sale |
45.36 |
860,123 |
39,014,046 |
219,405 |
2.64%
大文字化:
|
ボリューム (24 時間):